Translate Register Log In Login with facebookLogin and Register

MS not treated by Vitamin D (a few old studies using small doses) – Meta-analysis July 2018

The efficacy of vitamin D in multiple sclerosis: A meta-analysis

hengChaoa1 HeLiangb1 LiuLinglinga ZhuJieac JinTaoa
Multiple Sclerosis and Related Disorders, Volume 23, July 2018, Pages 56-61, https://doi.org/10.1016/j.msard.2018.05.008


It examined only 6 studies
The most recent study was from 5 years before
Doses sizes included 3,000 IU average (20,000 Weekly)
The meta-analysis, as is typical, ignored dose sizes
This meta-analysis also ignored the type of Vitamin D used (0.5 microgram of Calcitriol)

See also VitaminDWiki

The articles in both of the categories MS and Meta-Analysis are:

MS Intervention using Vitamin D:

PDF available free at Sci-Hub

Multiple sclerosis (MS) is a chronic inflammatory demyelination disorder in the central nervous system (CNS) leading to a high level of neurological disability. The pathogenesis of MS remains largely unknown, which explains the lack of significant efficacy of therapy in MS. Vitamin D deficiency is widely considered to be an environmental risk factor for MS. Many studies investigating the therapeutic effects of vitamin D on MS have been applied. The objective of this systematic review and meta-analysis was to evaluate the effectiveness of vitamin D in MS patients.

To obtain a more comprehensive estimate of the efficacy of vitamin D on MS patients, we conducted a meta-analysis to determine the role of vitamin D in MS. The PubMed, EMBASE and Cochrane databases were searched in October 2017. Randomized, double-blind, placebo-controlled clinical trials recorded within the three main databases were considered. The analysis was conducted for two specific outcomes: Expanded Disability Status Scale (EDSS) score and annual relapse rate (ARR).

Vitamin D3 as add-on treatment had no significant therapeutic effect on MS according to EDSS score (mean difference -0.01 95% CI -0.34 to 0.33). The ARR was higher in the vitamin D group than in the placebo group (mean difference 0.05 95% CI 0.01 to 0.1).

Our findings suggest that vitamin D appeared to have no therapeutic effect on EDSS score or ARR in the patients with MS.

Created by admin. Last Modification: Sunday May 27, 2018 12:59:28 GMT-0000 by admin. (Version 2)
See any problem with this page? Report it (FINALLY WORKS)